Discover the CRM diseases market's expansion to US$451.87 billion by 2033 with 4.8% CAGR. Key insights on cardiovascular's 57% share (US$170B in 2024), therapeutics dominance, and metabolic disorders' growth fueled by GLP-1 agonists and healthcare access in chronic condition management. https://finance.yahoo.com/news/cardiovascular-renal-metabolic-crm-diseases-143500544.html